Chicago Equity Partners’s Neurocrine Biosciences NBIX Stock Holding History

Chicago Equity Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$1.54M	Sell	17,825 -5,615	-24%	-$550K	0.16%	195
2019 Q4	$2.52M	Sell	23,440 -9,050	-28%	-$948K	0.14%	207
2019 Q3	$2.93M	Sell	32,490 -355	-1%	-$33.2K	0.14%	219
2019 Q2	$2.77M	Sell	32,845 -6,140	-16%	-$504K	0.12%	239
2019 Q1	$3.44M	Buy	38,985 +10,740	+38%	+$898K	0.13%	215
2018 Q4	$2.02M	Sell	28,245 -4,895	-15%	-$469K	0.08%	335
2018 Q3	$4.08M	Buy	33,140 +24,875	+301%	+$2.82M	0.12%	237
2018 Q2	$812K	Sell	8,265 -630	-7%	-$56.4K	0.02%	564
2018 Q1	$738K	Sell	8,895 -26,660	-75%	-$2.25M	0.02%	544
2017 Q4	$2.76M	Buy	+35,555	New	+$2.43M	0.08%	307

Other funds holding NBIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chicago Equity Partners's NBIX Position: Q1 2020 in Review

Chicago Equity Partners reduced its Neurocrine Biosciences (NBIX) stake by 24% in Q1 2020, selling an estimated $550K and leaving 17,825 shares worth $1.54M. The position accounts for 0.16% of the portfolio, ranked #195.

Chicago Equity Partners first reported a position in NBIX in Q4 2017 and has held it in 10 quarters since. The position peaked at $4.08M in Q3 2018. 368 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

Chicago Equity Partners held 17,825 shares of Neurocrine Biosciences worth $1.54M as of Q1 2020.
Chicago Equity Partners sold 5,615 Neurocrine Biosciences shares in Q1 2020, an estimated $550K.
Neurocrine Biosciences made up 0.16% of Chicago Equity Partners's portfolio in Q1 2020, its #195 holding.
Chicago Equity Partners first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 10 quarters since.
Chicago Equity Partners's Neurocrine Biosciences position peaked at $4.08M in Q3 2018.
368 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.